BioStem Technologies has appointed Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee. Ungrodt brings nearly three decades of financial leadership to the role, having spent her career as a senior partner at Ernst & Young advising life sciences companies. She is qualified to serve as a financial expert under SEC, NYSE, and NASDAQ rules.
As Audit Committee Chair, Ungrodt will oversee the company's financial reporting, internal controls and risk management practices. Her appointment comes at a pivotal time for BioStem, as the company undertakes an expansion of its business beyond chronic wound care and plans to raise its profile in the public markets in 2026. Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that Ungrodt's twenty-nine years of life sciences accounting experience at Ernst & Young, along with her track record advising more than thirty IPOs and deep regulatory expertise, will make a terrific addition to board governance.
Ungrodt's prior experience includes serving as Chair of the Audit Committee for Feeding San Diego, where she provided accounting, budgeting and risk assessment guidance for over a decade. She is also an Advisory Board Member for Life Science Cares. During her tenure at EY, Ungrodt served more than 70 companies across the Life Sciences sector. Ungrodt holds a BS in Accounting from San Diego State University and is a Certified Public Accountant.
BioStem is an emerging leader in placental and umbilical cord–derived tissue products used by clinicians across a variety of medical specialties. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks and are established in compliance with current Good Tissue Practices and current Good Manufacturing Processes.
Ungrodt replaces former board member Brandon Poe, who accepted the role of BioStem's chief financial officer in August 2025. Poe brings more than 25 years of finance leadership experience across the healthcare and life sciences sectors. He served on BioStem's Board of Directors for three years before joining the organization. The latest news and updates relating to BioStem are available in the company's newsroom at https://tinyurl.com/bsemnewsroom.
For business and technology leaders, this appointment signals BioStem's preparation for significant growth and potential public market activities. The addition of a seasoned financial expert with specific life sciences IPO experience suggests the company may be positioning itself for increased investor visibility and regulatory scrutiny as it expands its product portfolio. In the competitive MedTech sector, strong audit committee leadership is crucial for maintaining investor confidence during periods of rapid expansion and innovation.
